Oliver Dolan Sells Shares of Korro Bio, Inc. (KRRO)

Oliver Dolan, the Senior Vice President of Finance at Korro Bio, Inc., sold 3,383 shares of the company on June 16, 2026. The shares were sold at an average price of $10.83, bringing the total value of the transaction to approximately $36,637. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Korro Bio, Inc.

Several other insiders at Korro Bio also sold shares on the same day. Jeffrey Cerio, General Counsel, sold 6,609 shares, while Loic Vincent, Chief Scientific Officer, sold 3,418 shares. Additionally, Todd Chappell, Chief Operating Officer, sold 3,168 shares. On June 10, 2026, insiders Jean Francois Formela and Timothy Pearson each bought 14,677 shares.

Other Institutional Activity in Korro Bio

Among institutional investors, LYNX1 Capital Management LP significantly increased its position in Korro Bio by adding 860,381 shares, bringing its total holdings to 1,538,296 shares valued at approximately $17.4 million. NEA Management Company, LLC also upped its stake by 207,100 shares to a total of 1,297,893 shares worth about $14.7 million. Meanwhile, Atlas Venture Life Science Advisors, LLC maintained its position with 1,137,149 shares valued at $12.9 million.

Korro Bio, Inc. Stock Down 14.4%

Shares of Korro Bio (NasdaqCM: KRRO) are currently trading at $10.66. The company has a market capitalization of around $159.4 million. Korro Bio's forward P/E ratio is not meaningful due to its lack of profitability, and it has a beta of 2.096, indicating higher volatility compared to the market. The stock's 52-week range is between $5.20 and $55.89, with a 50-day moving average of $12.21 and a 200-day moving average of $17.76.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Korro Bio. On May 19, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $15.00 price target. Citigroup initiated coverage with a 'buy' rating and a $21.00 target on May 18, 2026. The consensus among 10 analysts is a 'buy' recommendation with a mean target price of $20.00.

About Korro Bio, Inc.

Korro Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing genetic medicines using RNA editing technology to treat rare and common diseases. The company's lead candidate is KRRO-121, aimed at treating hyperammonemia. Korro Bio is also working on treatments for conditions like Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018, the company collaborates with Novo Nordisk A/S to develop therapies for cardiometabolic diseases.

Bottom Line

Oliver Dolan's recent sale of shares is a notable insider transaction at Korro Bio. Investors often watch such moves for potential insights into company outlooks. The company remains a focus of institutional interest, with several funds adjusting their positions. Analysts continue to see potential in Korro Bio, reflected in their optimistic price targets.